ON12 Prostate Cancer

Beschreibung

PHCY320 (Oncology) Quiz am ON12 Prostate Cancer, erstellt von Mer Scott am 08/10/2019.
Mer Scott
Quiz von Mer Scott, aktualisiert more than 1 year ago
Mer Scott
Erstellt von Mer Scott vor etwa 5 Jahre
2
0

Zusammenfassung der Ressource

Frage 1

Frage
Epidemiology​: Median age at diagnosis is [blank_start]66[blank_end] years​. [blank_start]100%[blank_end] 5 year survival rate with local or regional disease​ [blank_start]28.7%[blank_end] 5 year survival rate with distant disease​ 95% are [blank_start]adenocarcinoma[blank_end](cancer that starts in the mucous glands in epithelial tissue). In New Zealand…​ [blank_start]Most common[blank_end] cancer in men (3000 new cases/year, 600 deaths/year)​.
Antworten
  • 66
  • 100%
  • 28.7%
  • adenocarcinoma
  • Most common

Frage 2

Frage
Which of these is NOT a risk factor for prostate cancer?
Antworten
  • Male
  • Age >40
  • Black (race)
  • Family history ​
  • Alcohol consumption

Frage 3

Frage
There is controversy with screening​ for prostate cancer as there is no clear evidence of mortality benefit with screening​.
Antworten
  • True
  • False

Frage 4

Frage
Screening methods: - Digital rectal exam (circa 1900s)​. [blank_start]Cheap, safe, easy[blank_end] BUT not [blank_start]sensitive[blank_end], poor interobserver reliability, poor [blank_start]compliance[blank_end]​ - PSA blood test (prostate specific antigen)​ Low [blank_start]specificity[blank_end]​. Many other causes (BPH, acute [blank_start]prostatitis[blank_end], urinary [blank_start]retention[blank_end],benign prostatic [blank_start]hypertrophy[blank_end])​.
Antworten
  • Cheap, safe, easy
  • sensitive
  • compliance
  • specificity
  • prostatitis
  • retention
  • hypertrophy

Frage 5

Frage
Select ALL the symptoms of prostate cancer which indicate advanced disease.
Antworten
  • Painful urination​
  • Erectile dysfunction
  • Urinary hesitance​
  • Urinary retention​
  • Hematuria​
  • Weight loss​
  • Back pain​
  • Lower extremity oedema​
  • Anemia​

Frage 6

Frage
Diagnosis​ History and physical exam​. DRE​ and PSA. TRUS - [blank_start]transrectal ultrasound[blank_end] - if one of above positive). [blank_start]Biopsy[blank_end] (confirmative)​
Antworten
  • transrectal ultrasound
  • Biopsy

Frage 7

Frage
Staging: Stage A​ - [blank_start]Occult or palpable​[blank_end] Stage B​ -[blank_start]Confined to the prostate​[blank_end] Stage C​ - [blank_start]Localised to periprostatic area​[blank_end] Stage D​ - Metastatic disease ​ [blank_start]T0N0M0[blank_end] (non-palpable)​ [blank_start]T1[blank_end]​ - Not palpable or visible by imaging​ [blank_start]T2[blank_end]​ - Confined within prostate​ [blank_start]T3[blank_end]​ - Extends through capsule​ [blank_start]T4​[blank_end] - Fixed or invades adjacent structures (other than seminal vesicles)​
Antworten
  • Occult or palpable​
  • Confined to the prostate​
  • Localised to periprostatic area​
  • T0N0M0
  • T1
  • T2
  • T3
  • T4​

Frage 8

Frage
Gleason Score​: Histologic grade of tumor​. Calculated based on dominant [blank_start]histological[blank_end] grades. Scores range from 1 = well [blank_start]differentiated[blank_end] healthy tissue, to 5 = very [blank_start]poorly[blank_end] differentiated​ abnormal tissue. Gleason score = sum of [blank_start]two most common[blank_end] pattern grades ([blank_start]2 to 10[blank_end])​. Higher is worse.
Antworten
  • histological
  • differentiated
  • poorly
  • two most common
  • 2 to 10

Frage 9

Frage
Factors influencing prognosis:​ Extent of [blank_start]tumor[blank_end]​ Histological [blank_start]grade[blank_end] of tumor​ Patient’s [blank_start]age and health​[blank_end] [blank_start]Molecular markers[blank_end] (Bcl-2, Bax, Ki67, p53, p27, E-cadherin, Microvessel density, DNA ploidy, p16)​ PSA level? ​
Antworten
  • tumor
  • grade
  • age and health​
  • Molecular markers

Frage 10

Frage
Initial treatment depends on the stage, Gleason score, presence of symptoms, and life expectancy​. Low risk patients (T1 or T2, GS of [blank_start]2-6[blank_end], PSA<10ng/ml) – excellent survival (10yr)​: [blank_start]Observation​Radiation​[blank_end] Radical [blank_start]prostatectomy ​[blank_end] Life expectancy <10 years​? Observation​ Radiation therapy ​
Antworten
  • 2-6
  • prostatectomy ​
  • Observation​, radiation​

Frage 11

Frage
Nonpharmacological Treatments: Observation​ - DRE and PSA performed every [blank_start]6[blank_end] months and biopsy if signs of [blank_start]progression[blank_end]​ Radiation​ - Effective yet complications ([blank_start]hematuria, impotence, diarrhea, cystitis[blank_end])​ Radical prostatectom y - Complications: [blank_start]blood loss[blank_end], impotence, [blank_start]incontinence[blank_end], fistula​ Bilateral orchiectomy (removal of testes)​. Need [blank_start]androgen deprivation therapy[blank_end]​.
Antworten
  • 6
  • progression
  • hematuria, impotence, diarrhea, cystitis
  • blood loss
  • incontinence
  • androgen deprivation therapy

Frage 12

Frage
Hormonal Treatment​: Rationale​ - Androgens stimulate prostate cancer cells to [blank_start]grow[blank_end]. Main androgens are [blank_start]testosterone[blank_end] and dihydrotestosterone (DHT)​. Most androgens made by [blank_start]testicles[blank_end] but also by adrenal glands​. Lowering androgen levels makes prostate cancer cells shrink or grow more [blank_start]slowly[blank_end] but does not cure prostate cancer. Indication​ - If cancer cannot be cured by surgery or radiation or [blank_start]remains/relapses[blank_end]​... In combination with radiation therapy if high [blank_start]risk of recurrence[blank_end] (high Gleason)​... OR before radiation to shrink cancer and make radiation more [blank_start]effective[blank_end] .
Antworten
  • grow
  • testosterone
  • testicles
  • slowly
  • remains/relapses
  • risk of recurrence
  • effective

Frage 13

Frage
Pharmacological (hormone) Treatment​: 1. LHRH [blank_start]agonists[blank_end]​ - Reversible method of androgen ablation as effective as orchiectomy​. Puts patient at risk for [blank_start]osteoporosis[blank_end]​. Drugs: [blank_start]Leuprolide, Goserelin,[blank_end] Triptorelin, Histrelin​. 2. GnRH [blank_start]antagonists[blank_end]​ - Works directly in [blank_start]pituitary[blank_end] to reduce testosterone ​ 3. Antiandrogens - Bind to [blank_start]androgen[blank_end] receptors so androgens cannot. Not used alone, typically with LHRH agonists/removal of testicles. Drugs: [blank_start]Flutamide, Bicalutamide, Nilutamide​[blank_end]
Antworten
  • agonists
  • osteoporosis
  • Leuprolide, Goserelin,
  • antagonists
  • pituitary
  • androgen
  • Flutamide, Bicalutamide, Nilutamide​

Frage 14

Frage
Which of these is not an ADR of androgen lowering therapies?
Antworten
  • Reduced or absent sexual desire​
  • Erectile dysfunction​
  • Shrinkage of testicles and penis​
  • Hot flushes​
  • Osteoporosis
  • Anemia​
  • Loss muscle mass​
  • Weight gain​
  • Depression​
  • Weight loss
Zusammenfassung anzeigen Zusammenfassung ausblenden

ähnlicher Inhalt

Oncology Final MCQs 1- 5th Year PMU
Med Student
Test of Nuclear Medicine- Oncology 5th Year PMU
Med Student
Neurosurgery Module II - Neuro-oncology
Matthew Coulson
Cancer Genetics
Farrah
PATHO LE2: Neoplasia
Jessica Margaux Mercado
HPV Natural history
Nicole Neumann
Introduction to Oncology - Drugs
Ryan Kidd
Approach to childhood malignany
Averil Tam
Hematology
annerao
Oncology
James Sante
Oncology Quiz #1
Mostapha Abdelkader